Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The consensus price target hints at a 63.7% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here is how Intellia Therapeutics, Inc. (NTLA) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

Shares of Intellia Therapeutics (NTLA -0.29%), a small-cap biotech company, are up by 63% this year. The company is benefiting from substantial clinical progress, and judging by price targets set by Wall Street analysts, there's still plenty of upside left for the stock.

CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.

Cathie Wood is having a good year. The Ark Invest founder, CEO, and ace stock picker isn't back to her peak 2020 form when many of her exchange-traded funds (ETFs) more than doubled in value.

Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).

CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Results were presented in an oral session on Thursday, September 25 at the 5th International ATTR Amyloidosis Annual Meeting for Patients and Doctors in Baveno, Italy. The results were simultaneously published in the New England Journal of Medicine, and the presentation will be available on the Scientific Publications & Presentations section of intelliatx.com.

News shared this week that Intellia Therapeutics, Inc.'s pivotal study of candidate lonvo-z is fully enrolled has been greeted warmly by the market, with good reason. NTLA stock remains a compelling Buy, driven by strong progress in its late-stage gene editing therapies for HAE and ATTR-CM. NTLA's lead candidate, lonvo-z, has completed Phase 3 enrollment for HAE, offering a one-time infusion advantage over competitors and strong regulatory support.

Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.

Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced it has completed enrollment in the global Phase 3 HAELO study of lonvoguran ziclumeran (lonvo-z) for the treatment of hereditary angioedema (HAE). Topline data are expected in the first half of 2026. Intellia is on track to submit a biologics license application (BLA) in the second half of 2026 to support the company's plans for a U.S. launch in the first half of 2027.

Cathie Wood is known for seizing opportunities. The founder of Ark Invest doesn't worry when one of the stocks she's invested in drops, and instead, she looks at the movement as a chance to increase her bet -- at a great price.

Intellia Therapeutics (NASDAQ: NTLA) has been getting a lot of buzz lately among investors who follow the biotech space. The company uses CRISPR gene editing technology to develop treatments, and while their stock has been all over the place historically, something's changed in 2025 that has people taking notice.

Intellia Therapeutics, Inc.'s lead gene-editing therapies, Lonvo-z and Nex-z, show best-in-class potential with 'one and done' treatment and strong early efficacy and safety data. Recent safety concerns in ATTR-CM seemed to be resolved quickly, and robust patient demand in pivotal trials support confidence in upcoming Phase 3 data and commercial launches. Cash runway extends into late 2026, but pivotal 2025 catalysts and potential blockbuster approval in multi-billion dollar markets could drive significant upside.

NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.